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Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a 
rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those 
with chronic gastroesophageal reflux disease (GERD) and at least two risk factors (e.g., >50 
years, white race, obese, tobacco smoking history).2,3 However, providing clinicians with a tool 
that allows them to estimate a patients’ risk may better aid them in deciding who to screen for 
BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus 
pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using 
information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-
years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well 
between men with and without BE, with an area under the receiver operating characteristic 
curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 
vs. 0.61, p<0.001).4 However, this prediction tool needs to be validated in an independent 
population before its use can be recommended in clinical practice.5  
 
Methods 
We examined the predictive performance of the M-BERET using data from four separate 
population-based case-control studies in the Barrett’s and Esophageal Adenocarcinoma 
Consortium (http://beacon.tlvnet.org/): 282 cases and 434 controls in the Houston BE study; 140 
cases and 162 controls in the Factors Influencing the Barrett’s/Adenocarcinoma Relationship 
study (based in Ireland; “FINBAR”); 128 cases and 128 controls in the Study of Digestive Health 
(based in Australia; “SDH”); and 45 cases and 73 controls in the Study of Reflux Disease 
(based in western Washington State; “SRD”). In all four datasets, cases included persons with 
BE defined by endoscopic evidence of columnar mucosa in the tubular esophagus, 
accompanied by the presence of specialized intestinal metaplasia in an esophageal biopsy. 
Cases were compared with population-based controls, representing the underlying source 
population from which cases arose. We restricted our analyses to men aged between 50 and 79 
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years because this was the population in which M-BERET was developed4 and this represents 
the population at greatest risk for BE.  
 
Statistical analysis 
Analyses were performed separately in the four studies and we used the following 
formula to determine BE risk according to the M-BERET (http://mberet.umms.med.umich.edu/): 
Logit[Prob(BE)] = -9.1422 + (0.04278 x age) + (0.8453 if weekly GERD) + (3.6682 x WHR) + 
(0.00835 x pack-years). We quantified the discriminatory ability of the M-BERET using the 
AUROC. To be useful, the M-BERET’s predicted risks must discriminate (separate) well 
between those participants who do have BE (cases) and those participants who do not have BE 
(population-based controls). The AUROC gives the probability that for any randomly selected 
pair of individuals, one case and one control, the model assigns a higher probability to the case. 
A value of 1 indicates the model has perfect discrimination, while a value of 0.5 indicates the 
model discriminates no better than chance. A moderately predictive AUROC ranges from 0.7 to 
0.8 and indicates acceptable model discrimination.5 All statistical analyses were conducted 
using SAS 9.4. 
 
Results 
Mean age of the study populations ranged from 60 to 65 years. In each study, BE cases 
had higher WHR, greater pack-years smoked and were more likely to have frequent GERD 
symptoms, compared with controls. When the M-BERET was applied separately to each study, 
it achieved similar discrimination accuracy between cases and controls in each study: Houston, 
AUROC=0.71, 95%CI=0.67-0.75; FINBAR, AUROC=0.70, 95%CI 0.64-0.76; SDH, 
AUROC=0.72, 95%CI=0.66-0.78; and SRD, AUROC=0.70, 95%CI=0.60-0.79 (Figure 1a-d). 
These compare favorably with the AUROC in the original study (0.72),4 showing little evidence 
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for over-fitting or optimism. The AUROC was higher for long-segment BE (pooled analysis of 
270 long-segment BE vs. 669 controls, AUROC=0.73, 95%CI=0.70-0.77). 
 
Discussion 
Prediction models are increasingly common in the medical literature and may have a 
role in disease prevention as well as diagnosis and treatment of patients. However, despite the 
large number of models developed and published, few are externally validated and fewer are 
used in clinical practice.6 In this study, we externally validated the M-BERET in four independent 
datasets and confirm that it discriminates patients with BE from population-based controls with 
reasonable accuracy. However, BE is relatively rare,7 and the number of people who actually 
have BE as a proportion of those predicted to do so will be low. Thus, even in this setting where 
M-BERET shows high discriminatory power, most people exposed to the risks of further 
investigation (i.e., endoscopy) will not see any benefit. While the M-BERET has the potential to 
allow for more efficient screening for BE, blood based biomarkers may augment or even replace 
this model.8  
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